MICROHEALTH MEANS BETTER PATIENT CONNECTIONS

MicroHealth provides innovative patient connections to help inform hemophilia treatment decisions and stay on track.

INDICATION

ALTUVIIIO® is indicated for use in adults and pediatric patients with hemophilia A (congenital factor VIII deficiency) for:

- Routine prophylaxis to reduce the frequency of bleeding episodes
- On-demand treatment & control of bleeding episodes
- Perioperative management of bleeding

Limitation of Use

ALTUVIIIO is not indicated for the treatment of von Willebrand disease.

Please see additional Important Safety Information and full Prescribing Information.

ALTUVIIIO® Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl + microhealth

KEEPING PATIENTS ON TRACK

MicroHealth™* is the world's largest digital health network for the hemophilia community. By working with MicroHealth, you and your team help keep your patients on track and stay connected via mobile and web apps.

MicroHealth is proudly sponsored by Sanofi.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS:

ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

*MicroHealth is an independent health network for digital hematology. Sanofi does not have access to any personal information collected by MicroHealth.

ALTUVIIIO® Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl

WHAT YOU NEED TO KNOW

- Monitor treatment, view patients' bleeds
- Review adherence, receive clinical notifications when patients are noncompliant
- Identify patients who may benefit from additional support
- Stay connected with patients via mobile and web apps

Patients on ALTUVIIIO can access information about financial assistance and other patient support services available to help support them throughout their treatment.

IMPORTANT SAFETY INFORMATION (CONT'D)

WARNINGS AND PRECAUTIONS:

- Allergic-type hypersensitivity reactions, including anaphylaxis, have occurred with ALTUVIIIO. Discontinue use of ALTUVIIIO if hypersensitivity reaction occurs and manage symptoms as appropriate.

Please see additional Important Safety Information and full Prescribing Information.

ALTUVIIIO®
Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl

GETTING STARTED IS EASY

Set up an account for your practice quickly and easily by visiting MicroHealth.org.

- Choose what types of notifications to get about your patients, such as frequency of bleeds, or when adherence drops below a certain level
- When your patients connect with you on MicroHealth, you can see their treatment schedules, bleed logs, adherence level ratio, their factor and dosage, even pictures they've shared of bleeds and what caused them
- Send and receive private messages, and accept appointments, if necessary. Patients receive communications from you via the web or on their mobile devices

Sign up your center at MicroHealth.org; then, inform your patients your center is using the app.

IMPORTANT SAFETY INFORMATION (CONT'D)

WARNINGS AND PRECAUTIONS (CONT'D):

- Formation of neutralizing antibodies (inhibitors) to Factor VIII has been reported following administration of ALTUVIIIO. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests.

Please see additional Important Safety Information and full Prescribing Information.

The cloud-based, user-friendly app that gives medical professionals access to patient information by tracking treatment regimens in a smart and synced format.*

Scan the QR code to sign up and get started.



*MicroHealth is an independent health network for digital hematology. Sanofi does not have access to any personal information collected by MicroHealth.

ALTUVIIIO®

Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl

RESOURCES TO SUPPORT YOUR PATIENTS

Visit ALTUVIIIOHCP.COM

Learn about all the resources, support, and financial assistance options available to your patients, including Free Trial Program†, Copay Assistance Program‡, and Patient Assistance Program†.

†Free Trial valid only for a patient's first prescriptions and it is limited to one use per patient per product for their lifetime. Free Trial not valid in Vermont. Claims for free products dispensed through the Free Trial or Patient Assistance Programs shall not be submitted to any third-party payer, public or private (e.g. private insurance, Medicaid, Medicare, VA, DoD, TRICARE®, or similar federal or state programs) for reimbursement. All Programs not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Programs at any time without notice. Program details provided upon registration.

‡Not valid if the patient is utilizing a state or federally funded health insurance program such as Medicare (including Medicare Part D), Medicaid, Medigap, VA, DoD, TRICARE®, state pharmaceutical assistance program, etc. to pay in part or in full for their ALTUVIIIO prescription. Not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Copay Program at any time without notice. Savings by patients may vary depending on their out-of-pocket costs. The program is intended to help patients afford their ALTUVIIIO prescription. Patients may have insurance plans that attempt to dilute the impact of the assistance available under the program. In those situations, the program may change its terms.

ALTUVIIIO®

Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl

INDICATION

ALTUVIIIO® is indicated for use in adults and pediatric patients with hemophilia A (congenital factor VIII deficiency) for:

- Routine prophylaxis to reduce the frequency of bleeding episodes
- On-demand treatment & control of bleeding episodes
- Perioperative management of bleeding

Limitation of Use

ALTUVIIIO is not indicated for the treatment of von Willebrand disease.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS:

ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

WARNINGS AND PRECAUTIONS:

- Allergic-type hypersensitivity reactions, including anaphylaxis, have occurred with ALTUVIIIO. Discontinue use of ALTUVIIIO if hypersensitivity reaction occurs and manage symptoms as appropriate.
- Formation of neutralizing antibodies (inhibitors) to Factor VIII has been reported following administration of ALTUVIIIO. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests.
- If assessment of plasma Factor VIII activity is needed, it is recommended to use a validated one-stage clotting assay. The ALTUVIIIO Factor VIII activity level is overestimated by the chromogenic assay and a specific ellagic acid-based aPTT reagent in one-stage clotting assay by approximately 2.5-fold. If these assays are used, divide the result by 2.5 to approximate the patient's ALTUVIIIO Factor VIII activity level.

ADVERSE REACTIONS:

The most common adverse reactions (>10% of subjects) reported in clinical trials were headache and arthralgia.

Please see full Prescribing Information.

sanofi

MAT-US-2300373-v4.0-03/2026